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Bcl-xL anti-apoptotic proteinToxoplasma gondii is a protozoan parasite that can infect all warm blooded animals including humans.
During natural course of T. gondii infection, bradyzoites or sporozoites invade the intestinal cells and turn
into tachyzoite form in 12–18 h. Therefore, a vaccine against toxoplasmosis is required to induce protec-
tive immune response initially in intestines against bradyzoites or sporozoites. The present study aimed
to generate a DNA vaccine containing a sporozoite speciﬁc surface antigen ‘‘SporoSAG’’. To increase anti-
gen speciﬁc-CD8+ T lymphocyte response, anti-apoptotic Bcl-xL gene was inserted to vaccine as a molec-
ular adjuvant.
For the construction of DNA vaccine, SporoSAG gene was inserted after CMV promoter and Bcl-xL gene
was inserted in frame with EGFP after IRES promoter (pSporoSAG/Bcl-xL). Bcl-xL expression and func-
tionality as well as humoral and cellular immune responses were demonstrated by Western blotting
and ﬂow cytometer.
Western blotting and ﬂow cytometer analyses rationalized Bcl-xL expression that impedes apoptotic
cell death. The ratio of pSporoSAG/Bcl-xL transfected cells were signiﬁcantly higher than empty pEGFP
control plasmid (P < 0.05). Analysis of sera obtained from vaccinated mice showed strong anti-SporoSAG
speciﬁc IgG response. The ratio of CD8+ T lymphocytes secreting IFN-c signiﬁcantly increased compared
to controls (P < 0.0001), indicative of protection against toxoplasmosis.
The results of this study reveal the ability of SporoSAG protein to induce CD8+ T lymphocyte response
for the ﬁrst time. Overall, SporoSAG protein can be included to multivalant vaccine formulations in future
studies to increase the protection in infections acquired through T. gondii oocysts.
 2014 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Toxoplasma gondii is an obligate intracellular parasite infecting
all warm-blooded animals, including humans. T. gondii infection
causes congenital toxoplasmosis in newborns that may lead to
fetal anomalies, retinochoroiditis leading to blindness, lethal toxo-
plasmic encephalitis in immune compromised patients, and organ
failure in transplantation patients. Currently, toxoplasmosis is
linked to schizophrenia and other mental disorders [1,2].Worldwide, 500 million people are estimated to be infected
with T. gondii. Infection rates among pregnant women range from
37% to 58% in Europe, 10.8% in USA, and 30 to 60% in Turkey [3–6].
In United States, 400–4000 infants are estimated to born with con-
genital toxoplasmosis each year and up to 1,26 million cases of
ocular toxoplasmosis are detected [6,7].
The present drugs are not 100% effective against toxoplasmosis
and thus, a vaccine appears as an alternative in protection against
T. gondii infections. Finally, after classiﬁcation of T. gondii oocysts in
category B bioterrorism agents as a water safety threat, the
demand for a protective vaccine against toxoplasmosis has
increased [8]. This remark was supported by tainted water out-
breaks such as the British Columbia, Great Victoria outbreak
(affected 7718 people), Santa Isabel do Ivai outbreak (located in
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outbreak (affected 171 Air force academy recruits) [6,9,10].
T. gondii is acquired naturally through ingestion of tissue cysts
(contains bradyzoites) or oocysts (contains sporozoites). After the
ingestion, released sporozoites and bradyzoites invade the intesti-
nal cells and turn into tachyzoites in 12 and 18 h, respectively
[11,12]. To date, vaccine candidate antigens were almost always
selected randomly and mainly targeted to induce protective immu-
nity against the tachyzoite form of the parasite. Tachyzoites invade
host cells abruptly and immediately embed themselves in a protec-
tive parasitophorous vacuole (PV) in the host cell. In the PV, tach-
yzoites retain themselves from the host immune response. Almost
all of the vaccination strategies against the rapid tachyzoite inva-
sion form induced inadequate immune response to initiate clinical
studies. A preferred vaccine against toxoplasmosis has to induce
protective immune response against bradyzoites or sporozoites
during the initiation of infection as well as tachyzoites thereafter.
Protective immunity against T. gondii is achieved by Th1
responses. Therefore targeting MHC-I restricted antigens to induce
CD8+ T lymphocyte response is the sole aim of vaccine develop-
ment strategies [2,13]. The present study aimed to generate a
DNA vaccine containing a sporozoite speciﬁc surface antigen
‘‘SporoSAG’’ for the ﬁrst time, to block the sporozoites as they are
released from the oocysts in the intestine [14]. To increase the efﬁ-
cacy of the DNA vaccine, anti-apoptotic Bcl-xL (B-cell lymphoma-
extra large) gene was inserted to the dual expression vaccine plas-
mid as a molecular adjuvant to increase the antigen speciﬁc-CD8+ T
lymphocyte response.Materials and methods
DNA vaccine constructs
DNA vaccines were constructed using a dual promoter pIRE-
S2EGFP vector (Clontech, USA). The vaccines designed for this
study were pBcl-xL; encoding the Bcl-xL anti-apoptotic protein
gene (GenBank no: AAC53459.1), pSporoSAG; encoding SporoSAG
(GenBank no: AY492338) and pSporoSAG/Bcl-xL; encoding both
SporoSAG and Bcl-xL.
pBcl-xL plasmid was constructed as described [15] and the ﬁnal
pBcl-xL plasmid encoding Bcl-xL gene in frame with the EGFP
(Enhanced Green Fluorescent Protein) is under the control of the
IRES promoter. SporoSAG gene was isolated from pET28a/Sporo-
SAG plasmid by the following primers (SporoSAG forward:
50-AGATCTATGGGCAGCCATCATCATC-30 and SporoSAG reverse: 50-
AGATCTTCAGTGGTGGTGGTGGTGC-30) containing the BglII restric-
tion site to be cloned within the unique BglII site of the pIRE2EGFP.
The pSporoSAG and the pSporoSAG/Bcl-xL plasmids express the
SporoSAG protein under the control of the CMV (Cytomegalovirus)
promoter.
To facilitate the excision of the amplicons with the correspond-
ing restriction enzymes, cloning of all intermediate Polymerase
Chain Reaction (PCR) products and their subsequent clonings in
the ﬁnal plasmids were performed with the pGEMT-Easy plasmid
kit (Promega, USA) according to the manufacturer’s protocol. The
sequences were conﬁrmed by automatic sequencing using the
ABI Prism Big Dye Terminator Cycle Sequencing kit (Applied Bio-
systems, USA) and the BioEdit genetic analyzer (Ibis Biosciences,
USA).In vitro transfection of Baby Hamster Kidney (BHK) 21 cells and
Western blotting
Baby Hamster Kidney (BHK) 21 cells (ATCC No: CCL-10) are
transfected with pBcl-xL, pSporoSAG, pSporoSAG/Bcl-xL and emptypEGFP plasmids in 10 cm diameter culture dishes using the Lipo-
fectamine 2000 reagent (Invitrogen, USA) according to the manu-
facturer’s protocol. After 48 h, in vitro transfection efﬁcacies were
observed by EGFP expression using ﬂuorescence microscopy. Next
the cells were harvested to evaluate the in vitro expression of plas-
mids encoding Bcl-xL protein by Western blotting.
BHK-21 cells were scraped from 10 cm-diameter culture dishes
and counted with a hemocytometer. Equal amount of transfected
BHK-21 cells (approximately 5  105 cell per each sample) were
washed thrice with 1  PBS (Phosphate buffered saline, pH: 7.4)
followed by several cycles of freezing and thawing. Then lysed
samples were separated by 12% sodium dodecyl sulfate–polyacryl-
amide gel (SDS–PAGE). The separated proteins were transferred to
a polyvinylidene diﬂuoride (PVDF) transfer membrane (Immobi-
lon-P, Millipore, USA). Thereafter, the membranes were probed
with a 1:1000 dilution of the monoclonal anti-Bcl-xL Mab (Santa
Cruz Biotech, USA) and next, the membranes were probed with a
1:1000 dilution of alkaline phosphatase-conjugated goat anti-
mouse IgG (H+L) antibody (Bio-Rad, USA). The blot was developed
in diethanolamine buffer (10% Diethanolamine, 0.5 mM MgCl26H2
O, pH: 9.8) containing 4.3% 5-bromo-4-chloro-3-indolyl phosphate
(diluted in dimethylacetamide), 4.1% Nitro-BT (diluted in 70% (v/v)
dimethylformamide) (Applichem, Germany) [15,16].
Determining the cell survival effect of Bcl-xL protein
To determine the cell survival effect of Bcl-xL protein, BHK-21
cells were serum deprived 48 h after transfection with pBcl-xL,
pSporoSAG, pSporoSAG/Bcl-xL and empty pEGFP plasmids as
described [15,17]. Brieﬂy, BHK-21 cells were transfected with
2 lg of DNA vaccine plasmids using Lipofectamine 2000 (Invitro-
gen) for 4 h using OPTIMEM (Invitrogen). Next, cells were cultured
in 10% FBS (Fetal Bovine Serum) supplemented GMEM (Biochrome,
Germany) overnight. Then, the cells were washed thrice and main-
tained for an additional 48 extra hours in media without FBS.
Finally, cells were harvested, washed thrice and ﬁxed with Cyto-
ﬁx/Cytoperm solution (Becton Dickinson Biosciences, USA). There-
after, cells were washed thrice with Perm/Wash buffer and
resuspended in Ca+2–Mg+2 free PBS containing 1% inactive FCS
(Fetal Calf Serum), 0.09% (w/v) sodium azide (pH: 7.4). Cell survival
was determined by measuring EGFP in transfected cells using ﬂow
cytometer (FACSAria; BD Biosciences).
Animals and vaccination
Female 6–8 week-old Swiss outbred mice, obtained from Ege
University Experimental Animal Production Facility, were housed
and fed under standard, suitable conformist conditions. The exper-
imental plan was performed under the instructions and approval of
the Institutional Animal Care and Use Committee of Ege University
for animal ethical norms (Approval no: 2007-42).
Four groups of mice (four per each group) were vaccinated
thrice at three week intervals with pBcl-xL, pSporoSAG, pSporo-
SAG/Bcl-xL plasmids and empty pEGFP as negative control
(Table 1). The plasmids were puriﬁed using an endotoxin-free plas-
mid puriﬁcation kit (EndoFree, Qiagen, USA). During DNA vaccina-
tions 100 lg of plasmids was injected into both tibialis anterior
muscle of anesthetized mice. Tail bleeds were performed 3 weeks
after each vaccination for the detection of anti-SporoSAG speciﬁc
IgG antibodies.
Cloning of SporoSAG gene into bacterial expression vector
T7 promoter containing pET28a expression vector (10 lg;
5.3 kb; kanamycin resistant; Novagen, USA.) was linearized by
BamHI as described [16]. The following primers were designed to
Table 1
DNA vaccine and control plasmid doses and routes of administration used during vaccination of mice.
DNA vaccine groups Dose and route of administration
1st dose (day 0) 2nd dose (day 21) 3rd dose (day 42)
1 Empty pGFP 100 lg (i.m.) 100 lg (i.m.) 100 lg (i.m.)
2 pBcl-xL 100 lg (i.m.) 100 lg (i.m.) 100 lg (i.m.)
3 pSporoSAG 100 lg (i.m.) 100 lg (i.m.) 100 lg (i.m.)
4 pSporoSAG/Bcl-xL 100 lg (i.m.) 100 lg (i.m.) 100 lg (i.m.)
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ing by homologous recombination, 50-GTCGACAAGCTTGCGGCCGC-
ACTCGAGCACCAC-30 (forward primer, 33 nt) and 50-CAGCAAATG
GGTCGCGGATCCGAATTCGAGCTC-30 (reverse primer, 33 nt). The
linear acceptor vector was ampliﬁed and used during in vivo
recombination cloning.
PCR ampliﬁcation of SporoSAG gene
The backbone of SporoSAG (GenBank no: AY492338) gene was
kindly obtained from Prof. Michael White. Primers designed to
incorporate adapter termini into the PCR product to facilitate
directional cloning by homologous recombination (‘HiRec’) into
the pET28a vector. The primers for SporoSAG were 50-CAGCAAATG
GGTCGCGGATCCGAATTCGAGCTCTCGCTTCTTAGC CGAGTAGC-30
(forward primer, 53 nt) 30-CAGGGTTGGTGTACATGGCTGTCGACAA
GCTTG CGGCCGCACTCGAGCACCAC-50 (reverse primer, 53 nt).
SporoSAG gene was isolated from backbone DNA (1–10 ng) using
the designed primers (0.5 lM each), 2 U of TaqDNA polymerase
(Fermentas, Germany), 150 lM dNTPs and 1  TaqDNA polymer-
ase reaction buffer with the following calculated PCR protocol;
5 min initial denaturation step at 95 C, followed by 30 cycles of
0.5 min at 95 C, 0.5 min at 50 C, and 3.5 min at 72 C, and a ﬁnal
extension of 10 min at 72 C. The PCR products were visualized by
agarose gel electrophoresis, puriﬁed using a PCR puriﬁcation kit
(Qiagen, USA) and quantitated by spectrophotometry.
In vivo recombination cloning method
In vivo recombination cloning was performed as described [16].
Brieﬂy, linear pET28a vector, puriﬁed PCR product and DH5a cells
(Invitrogen) were mixed and heat shocked. Plasmids from over-
night culture were puriﬁed using plasmid puriﬁcation kit accord-
ing to the manufacturer’s protocol (Qiagen), visualized by
agarose gel electrophoresis and sequenced. The resulting plasmid
containing SporoSAG was named pET28a/SporoSAG.
Protein expression and puriﬁcation
Escherichia coli BL21 (DE3) chemically competent cells (Invitro-
gen) were transformed with pET28a/SporoSAG plasmid and grown
in 1 L LB with vigorous shaking at 37 C up to an optical density of
0.4, calculated at 600 nm. Then, the cells were induced with isopro-
pyl-b-D-thiogalactopyranoside (IPTG) to a ﬁnal concentration of
0.5 mM with vigorous shaking at 37 C for 4 h. The cells were cen-
trifuged at 5000g and the pellet was resuspended with prechilled
loading buffer (50 mM Tris–Cl, pH: 7.5, 0.3 M NaCl). Next, the cells
were disrupted with an M-110L microﬂuidizer processor (Micro-
ﬂuidics, USA) at low temperature under internal pressure of
18,000 psi. The processed sample was centrifuged at 30,000g
for ½ h at 4 C and clariﬁed supernatant was ﬁltered through a
0.45 lm ﬁlter (Corning, USA).
Puriﬁcation of the protein was performed by ÄKTA FPLC, a
liquid chromatography system, which is controlled by UNICORN™
software, using a 5 ml HiTrap Chelating HP column (GE Health,
USA). Clariﬁed ﬁltered supernatant was applied to the HiTrap
column with loading buffer. Then, the column was washed with150 mM imidazole containing 50 mM Tris–Cl, pH 7.5, 0.3 M NaCl
buffer. The recombinant SporoSAG (rSporoSAG) protein was eluted
by raising the imidazole concentration to 300 mM. The protein
fractions were detected by UV280, conﬁrmed by 12% SDS–PAGE,
pooled, and concentrated with Vivaspin ﬁlter unit (Sartorius,
Germany) at 4 C.
SDS–PAGE and Western blotting of rSporoSAG
Puriﬁed rSporoSAG protein separated by 12% SDS–PAGE was
transferred to PVDF transfer membrane and blocked by 0.25%
casein containing 1 TBS-T buffer (Tris buffered saline containing
Tween 20; 20 mM Tris–Cl pH: 7.8, 0.5 M NaCl, 0.5% Tween 20) for
30 min at room temperature. The membranes were probed with a
1:50 dilution of monoclonal anti-polyhistidine antibody (Sigma,
Germany) for 1.5 h. Next, the membranes were probed with a
1:2500 dilution of alkaline phosphatase-conjugated goat anti-
mouse IgG (H+L) antibody (Sigma). Thereafter the blot was devel-
oped as described above.
Detection of humoral immune response using Western blotting
To detect the anti-SporoSAG speciﬁc IgG antibody response,
rSporoSAG protein was transferred to PVDF as described above.
The membranes were incubated with a 1:100 dilution of vacci-
nated mouse sera for 1.5 h. Next, the membranes were incubated
with a 1:2500 dilution of alkaline phosphatase-conjugated goat
anti-mouse IgG (H+L) antibody (Sigma). Thereafter, the blot was
formed as described above to visualize the immune complexes
formed between rSporoSAG protein and anti-SporoSAG IgG anti-
bodies in the vaccinated mice sera.
Detection of cellular immune response
To determine the speciﬁc cellular immune response elicited by
each vaccine, mice were sacriﬁced three weeks after the third
immunization and their spleens were removed. Single cell suspen-
sions of splenocytes were prepared as described [16]. Aliquots of
5  105 viable splenocytes were added to each well of 96 well
round bottom plate (Nunc, USA). Before stimulation of splenocytes,
puriﬁed rSporoSAG protein was incubated with polymyxin B to a
ﬁnal concentration of 50 lg/ml for ½ h. Cells were stimulated with
12.5–25 lg/ml rSporoSAG protein for 72 h at 37 C and 5% CO2. As
positive control, splenocytes were incubated with concanavalin A
(Sigma) at a ﬁnal concentration of 10 lg/ml. As a negative control,
only growth medium was used.
During the last 4 h of incubation, monensin belonging to Cyto-
ﬁx/Cytoperm kit (BD Biosciences) was added to each well at a ﬁnal
concentration of 2 lM to allow the intracellular accumulation of
cytokines according to the manufacturer’s protocol.
T lymphocyte populations were surface stained with Alexa ﬂour
647 conjugated rat anti-mouse CD3 (Biolegend, USA), FITC conju-
gated rat anti-mouse CD4 (BD Biosciences), or FITC conjugated
rat anti-mouse CD8a (Abcam, USA), permeabilized with Cytoﬁx/
Cytoperm and labeled with an PE conjugated rat anti-mouse IFN-c
(Interferon-gamma) (BD Biosciences) or PE conjugated rat anti-
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to the manufacturer’s protocol.
Antibodies were diluted in Ca+2–Mg+2 free PBS with 1% inactive
FCS, 0.09% (w/v) sodium azide (pH7.4) for surface staining and in
Perm/Wash solution (BD Biosciences) for intracellular staining.
All antibodies were used at a ﬁnal concentration of 0.5 lg/106 cells.
T lymphocyte populations, gated in the ﬂow cytometer by CD3+
positive expression, were analyzed to quantify: the percentage of
rSporoSAG protein-speciﬁc CD8+ T lymphocytes secreting IFN-c
and CD4+ T lymphocytes that expressed IL-4.
Statistical analysis
Data obtained during the study were processed using Prism 5
(GraphPad, USA). A two-tailed unpaired t-test or one-way analysis
of variance with 95% conﬁdence interval was used to determine
the signiﬁcance between the vaccination groups. Results of cellular
immune response and BHK-21 cells transfection efﬁcacy were
expressed as mean ± standard deviation (S.D.).
Results
In vitro transfection
48 h after in vitro transfection, EGFP expression was determined
using ﬂuorescence microscopy (Fig. 1A). In vitro cell survival effect
of Bcl-xL inserted plasmids were determined under serum
deprived conditions. The percentage of surviving transfected-cells
was followed by detecting the plasmid encoded EGFP positive cells
in a ﬂow cytometer. The ratio of pSporoSAG and pSporoSAG/Bcl-xL
transfected cells were signiﬁcantly higher than empty EGFP control
plasmid (P < 0.05; designated by ‘‘’’ in Fig. 1B). In addition, the
ratio of pBcl-xL plasmid transfected cells was higher than its coun-
terpart empty pEGFP which does not encode the Bcl-xL protein.
Moreover, the percentage of pSporoSAG/Bcl-xL plasmid transfected
cells was higher than that of pBcl-xL plasmid (Fig. 1B). It was
shown that Bcl-xL protected cells from serum deprived apoptosis.
BHK-21 cells transfected with empty pEGFP, pBcl-xL, pSporo-
SAG and pSporoSAG/Bcl-xL plasmids were harvested after 48 h of
incubation and analyzed by Western blotting to determine the
correct expression of Bcl-xL anti-apoptotic protein. The anti-Bcl-Fig. 1. Determination of in vitro transfection efﬁciency by ﬂuorescence microscopy
and ﬂow cytometer. (A) EGFP expressing BHK-21 cells shown in bottom lane (B)
EGFP expressing BHK-21 cell ratios transfected with pEGFP, pBcl-xL, pSporoSAG and
pSporoSAG/Bcl-xL plasmids under serum deprived conditions.xL monoclonal antibody detected the 26.6 kDa housekeeping Bcl-
xL gene encoded-protein (Fig. 2; lanes 1–4); and an additional
band of 54 kDa was also shown in cells transfected with either
pBcl-xL or pSporoSAG/Bcl-xL plasmids corresponding to the fusion
of the EGFP and Bcl-xL proteins (Fig. 2; lanes 2 and 4).Anti-SporoSAG humoral immune response
The calculated molecular mass of the rSporoSAG protein,
expressed from the 1035 bp ORF, is 36.06 kDa which is detected
by monoclonal anti-polyhistidine antibody (Fig. 3; lane 1). To
determine the humoral immune response, rSporoSAg protein was
probed with a pool of serum samples obtained from each group
of vaccinated Swiss mice. The mice groups vaccinated with pSporo-
SAG and pSporoSAG/Bcl-xL induced a strong IgG response against a
36 kDa protein as detected by Western blotting (Fig. 3; lanes 4 and
5). No antibody response was detected in the control groups, in
which mice were vaccinated with empty pEGFP and pBcl-xL
(Fig. 3; lanes 2 and 3).Cell-mediated immune response to rSporoSAG expressing DNA
vaccines
Splenocytes from individual immunized mice were stimulated
in vitro with 12.5 lg/ml puriﬁed rSporoSAG protein. Flow cytome-
ter analysis was used to determine the ratio of CD4+ and CD8+ T
lymphocytes excreting IFN-c and IL-4 achived by the rSporoSAG
expressing DNA vaccines. Vaccine induced IFN-c and IL-4 secre-
tions are indicators of Th1 and Th2 like responses, respectively.
Protection against T. gondii is primarily achieved by CD8+ T lym-
phocytes excreting IFN-c [2,13].
The CD4+/CD8+ cell ratios of all vaccination groups were shown
in Fig. 4A. In this analysis, all vaccination groups were signiﬁcantly
higher than empty pEGFP control (P < 0.01; designated by ‘‘’’ in
Fig. 4A). The ratio of CD8+ T lymphocytes excreting IFN-c of all vac-
cination groups were signiﬁcantly higher than empty pEGFP con-
trol (P < 0.001; designated by ‘‘’’ in Fig. 4B). In addition, the
ratio of CD8+ T lymphocytes excreting IFN-c in pSporoSAG/Bcl-xL
vaccinated group was signiﬁcantly higher compared to pSporoSAG
vaccinated control group (P < 0.0001). The ratio of pSporoSAG con-
trol group was signiﬁcantly higher compared to control group mice
vaccinated with empty pEGFP (P = 0.0005). The ratio of CD8+ T
lymphocytes excreting IFN-c in pSporoSAG/Bcl-xL vaccinated
group was signiﬁcantly higher than pSporoSAG (P < 0.0001) and
pBcl-xL (P < 0.05) control groups. The ratio of CD8+ T lymphocytesFig. 2. Determination of in vitro transfection efﬁciency using Western blotting:
Detection of Bcl-xL expression using protein lysates obtained from cells transfected
with empty pEGFP (lane 1), pBcl-xL (lane 2), pSporoSAG (lane 3), pSporoSAG/Bcl-xL
(lane 4).
Fig. 3. Determination of anti-SporoSAG IgG antibody responses induced by
vaccinations. Lane 2: Probe of rSporoSAG protein using pooled sera of mice
vaccinated with empty pEGFP (lane 2), pBcl-xL (lane 3), pSporoSAG (lane 4),
pSporoSAG/Bcl-xL (lane 5). Puriﬁed rSporoSAG has been probed with anti-poly
histidine antibody (lane 1).
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oroSAG vaccinated control group (P = 0.0001).
CD4+ T lymphocytes excreting IL-4 ratio of all vaccination
groups were signiﬁcantly higher than empty pEGFP control
(P < 0.0001; designated by ‘‘’’ in Fig. 4C). The level of CD4+ T
lymphocytes excreting IL-4 was in pBcl-xL group was signiﬁcantly
higher than pSporoSAG vaccinated control group (P < 0.01). The
ratio of CD8+ T lymphocytes excreting IFN-c in pSporoSAG/Bcl-xL
vaccinated group was signiﬁcantly higher than pBcl-xL control
group (P < 0.05). pSporoSAG/Bcl-xL vaccinated group as signiﬁ-
cantly higher than pSporoSAG vaccinated control group
(P = 0.0004).
Overall, the pSporoSAG/Bcl-xL induced strong IFN-c secreting
CD8+ T lymphocyte response which is protective against T. gondii.
In addition, pSporoSAG/Bcl-xL induced strong IL-4 secreting CD4+Fig. 4. Determination of anti-SporoSAG speciﬁc T lymphocyte response after vaccination
ratio; (B) rSporoSAG protein speciﬁc CD8+ T lymphocytes secreting IFN-c; (C) rSporoSAGresponse indicative of Th1/Th2 balanced response. CD3+ cells from
all experimental and control groups proliferated to comparable
levels in response to concanavalin A.Discussion
Since 1990s, several vaccine candidate antigens have been
tested mainly using DNA vaccine formulations against mostly the
tachyzoite form of the parasite. The antigens used in these studies
are from SRS family proteins (SAG1, SAG2, SAG3, and SAG2CDX)
[18–21], micronemal proteins (MIC1, MIC2, MIC3, MIC4, MIC6,
MIC8, MIC11, and MIC13) [22–28], dense granule proteins (GRA1,
GRA2, GRA4, GRA6, and GRA7) [16,29–32], rhoptry proteins
(ROP1, ROP2, ROP4, ROP5, ROP7, ROP8, ROP16, and ROP18
[31,33–39], and other proteins such as RON4 [40], M2AP and
AMA1 [23], serin protease inhibitor-1 [41], immune mapped pro-
tein-1 [42], HSP70 and HSP30 [43], MAG1 [44], eukaryotic initia-
tion factor-2a [45], eukaryotic translation initiation factor 4A
[46], cyclophilin [47], calcium-dependent protein kinase 3 [48],
protein disulﬁde isomerase [49], aspartic protease 1 and cathepsin
proteases [50,51], perforin-like protein 1 [52], rhomboid protein 1
[53].
Protective immunity against T. gondii is achieved by Th1
responses, especially through IFN-c secreting CD8+ T lymphocytes
[2,13]. Therefore a vaccine against toxoplasmosis requires using
MHC-I restricted antigens to induce CD8+ T lymphocytes response.
Moreover a vaccine against toxoplasmosis is required to induce
protective immune response consecutively to all (bradyzoite/spo-
rozoite and tachyzoite) forms of the parasite since the tachyzoite
has the ability to invade the host cell abruptly and immediately
embeds itself in a protective parasitophorous vacuole which keeps
away the host immune response. Furthermore, in the natural route
of infection, only bradyzoites and sporozoites take place.
Oocysts are shed by infective felids to environment and spor-
ozoites form inside the oocyt at the end of sporulation process
which takes several days outside. Upon ingestion by the intermedi-
ate host, the sporozoites are released inside the distal intestine adusing Western Blotting. (A) rSporoSAG protein speciﬁc CD4+ and CD8+ T lymphocyte
protein speciﬁc CD4+ T lymphocytes secreting IL-4.
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cell invasion has not been clearly identiﬁed yet. However a two-
step process has been deﬁned for sporozoites wherein a primary
widened vacuole forms initially and then the sporozoite proceed
to form sophisticated and tighter secondary vacuole in which it
grows [54].
SporoSAG (TGME49_058550) is from the SRS family proteins of
T. gondii that is the most abundantly expressed protein on the
infectious sporozoite surface as shown by transcriptomic and pro-
teomic analysis conducted on oocysts/sporozoites [55,56]. Sporo-
SAG protein has attachment function for host cell invasion
[14,57]. The protective immune response stimulating efﬁcacy of
more than 40 antigens have been determined against toxoplasmo-
sis in previous studies however the most abundantly expressed
surface protein of sporozoite has not been evaluated yet. To dem-
onstrate the immune stimulating properties of SporoSAG protein, a
group of Swiss mice were experimentally infected with 8–10 fresh
sporulated oocysts (containing sporozoites) perorally and anti-
SporoSAG IgM and IgG antibodies were detected using a recombi-
nant ELISA by our study group (unpublished data).
Therefore, SporoSAG was selected as DNA vaccine candidate
antigen in this study due to its antigenic properties and role in host
cell invasion. Thereafter, a dual promoter DNA vaccine containing
SporoSAG and anti-apoptotic Bcl-xL gene was generated to
increase the antigen speciﬁc CD8+ T lymphocyte response. To
induce stronger immune responses by DNA vaccination, using
molecular adjuvants is a powerful approach. These molecular adju-
vants can be any immunogenic protein or any cytokine, chemokine
depending on the desired immune response to be elicited [58]. Bcl-
xL is an antiapoptotic Bcl-2 family member which is localized on
the outer membrane of mitochondria. There, it inhibits Bax (Bcl-
2 associated X protein; mostly found in cytosol and upon apoptosis
it is particularly associated to mitochondrial membrane forming
large oligomers that permeabilize the outer mitochondrial mem-
brane) induced pores, preventing the release of cytochrome c into
cytoplasm to induce caspase dependent cell death [59,60]. In addi-
tion, Bcl-xL protein was shown to increase the antigen speciﬁc
CD8+ T lymphocyte response in different DNA vaccination studies
[15,17]. In vitro study of a DNA vaccine encoding Bcl-xL against
FMD (Foot-and-mouth disease) showed that Bcl-xL signiﬁcantly
prolonged the survival of transfected cells (P < 0.001) [15]. In
another study, DNA vaccines encoding Bcl-xL and a part of human
papillomavirus type 16 (HPV-16) E7 proteins were administered
together and it has been showed that DNA vaccine encoding Bcl-
xL prolonged the E7-speciﬁc CD8+ T-cell responses [17]. Similarly,
a DNA vaccine encoding Single chain trimer (composed of the most
immunogenic epitope of human papillomavirus type 16 E6 protein,
beta2-microglobulin, and MHC class I heavy chain) DNA vaccine
combined with Bcl-xL increased E6-speciﬁc CD8+ T lymphocyte
immune response [61]. In the present study, in vitro cell survival
of pSporoSAG and pSporoSAG/Bcl-xL transfected cells were signif-
icantly higher than empty EGFP control plasmid (P < 0.05). More-
over, the percentage of pSporoSAG/Bcl-xL plasmid transfected
cells was higher compared to pBcl-xL plasmid (Fig. 1B). Western
blotting showed the accurate expression of Bcl-xL anti-apoptotic
protein in Bcl-xL expressing plasmids (Fig. 2). Altogether, Western
Blotting and ﬂow cytometer analyses rationalized Bcl-xL expres-
sion that impedes apoptotic cell death.
The ability of sporozoite surface protein ‘‘SporoSAG’’, to induce
protective immune response using a DNA vaccine has been evalu-
ated for the ﬁrst time in this study. According to the results, the
mice groups vaccinated with pSporoSAG/Bcl-xL DNA vaccine as
well as pSporoSAG control vaccine induced strong IgG responses
against recombinant SporoSAG protein (Fig. 3; lanes 4 and 5). A
protective DNA vaccine against toxoplasmosis has to induce IFN-
c secretion from CD8+ T lymphocytes. In the present study, theratio of CD8+ T lymphocytes excreting IFN-c in pSporoSAG/Bcl-xL
vaccinated group was signiﬁcantly higher compared to pSporoSAG
(P < 0.0001) and pBcl-xL (P < 0.05) control groups. In addition, the
ratio of pSporoSAG control group was signiﬁcantly higher com-
pared to control group mice vaccinated with empty pEGFP
(P = 0.0005). The results of IFN-c secreting CD8+ T lymphocytes
reveal the ability of SporoSAG protein to induce protective immune
response against toxoplasmosis. The higher ratios of CD8+ T lym-
phocytes excreting IFN-c in pSporoSAG/Bcl-xL and pBcl-xL groups
compared to pSporoSAG vaccinated group show the low CD8+ T
lymphocyte stimulating efﬁciency of SporoSAG protein when used
alone (Fig. 4B). In addition, pSporoSAG/Bcl-xL as well as pSporoSAG
induced strong IL-4 secreting CD4+ response indicative of Th2
polarized response (Fig. 4C). Altogether the pSporoSAG/Bcl-xL
seems to induce strong Th1 and Th2 responses at the same time
slightly biasing towards Th1 response which is an indication of
protection against toxoplasmosis.
Overall, an ideal vaccine against toxoplasmosis should sequen-
tially block the bradyzoites/sporozoites during the initial phase of
the infection as well as tachyzoites after stage conversion. There-
fore, a vaccine that protects from all forms of the T. gondii is
required. This aim can be achieved by using a highly antigenic pro-
tein expressed by all forms of the parasite or combining antigenic
proteins expressed by each form of the parasite in a multiprotein
vaccine formulation. The results of this study show that SporoSAG,
the most abundantly expressed protein on the surface of the spor-
ozoites, can be included to multivalant vaccine formulations in
future studies to increase the protective efﬁcacy of vaccines aiming
to protect infections acquired through ingestion of T. gondii
oocysts.Acknowledgements
This study was supported partly by the Grants given by The Sci-
entiﬁc and Technological Research Council of Turkey (107S359)
and the Ege University Science and Technology Center, Turkey
(2008BIL008) to Y.G. The authors would like to acknowledge
Michael White, Ph.D. for providing the backbone of SporoSAG gene.
The topic of the study received a research award from the Ege Uni-
versity, Science and Technology Center and presented orally in
20th ECCMID (European Congress of Clinical Microbiology and
Infectious Diseases) in Vienna, Austria, 2010. The authors state that
they have no conﬂict of interest.References
[1] J.G. Montoya, O. Liesenfeld, Toxoplasmosis, Lancet 363 (9425) (2004) 1965–
1976.
[2] L.M. Weiss, K. Kim, Toxoplasma gondii, The Model Apicomplexan: Perspectives
and Methods, Elsevier Ltd, Great Britain, 2007.
[3] S. Ertug, P. Okyay, M. Turkmen, H. Yuksel, Seroprevalence and risk factors for
toxoplasma infection among pregnant women in Aydin province, Turkey, BMC
Public Health 5 (2005) 66.
[4] S. Kuk, M. Ozden, A four-year investigation of the seropositivity of Toxoplasma
gondii in our hospital, Turkiye Parazitol. Derg. 31 (1) (2007) 1–3.
[5] M. Harma, M. Harma, N. Gungen, N. Demir, Toxoplasmosis in pregnant women
in Sanliurfa, Southeastern Anatolia City, Turkey, J. Egypt Soc. Parasitol. 34 (2)
(2004) 519–525.
[6] G.N. Holland, Ocular toxoplasmosis: a global reassessment. Part I:
epidemiology and course of disease, Am. J. Ophthalmol. 136 (6) (2003) 973–
988.
[7] J.L. Jones, D. Kruszon-Moran, K. Sanders-Lewis, M. Wilson, Toxoplasma gondii
infection in the United States, 1999 2004, decline from the prior decade, Am. J.
Trop. Med. Hyg. 77 (3) (2007) 405–410.
[8] NIAID (National Institute of Allergy and Infectious Diseases) Category A, B and
C Priority Pathogens, <http://www.niaid.nih.gov/topics/BiodefenseRelated/
Biodefense/Pages/CatA.aspx> (Erisim tarihi: 21.11.2013).
[9] W.R. Bowie, A.S. King, D.H. Werker, J.L. Isaac-Renton, A. Bell, S.B. Eng, et al.,
Outbreak of toxoplasmosis associated with municipal drinking water. The BC
Toxoplasma Investigation Team, Lancet 350 (9072) (1997) 173–177.
S. Gülçe _Iz et al. / Trials in Vaccinology 3 (2014) 81–88 87[10] L. Doganci, M. Tanyuksel, E.R. Araz, B.A. Besirbellioglu, U. Erdem, C.A. Ozoguz,
et al., A probable outbreak of toxoplasmosis among boarding school students
in Turkey, Clin. Microbiol. Infect. 12 (7) (2006) 672–674.
[11] J.P. Dubey, Bradyzoite-induced murine toxoplasmosis: stage conversion,
pathogenesis, and tissue cyst formation in mice fed bradyzoites of
different strains of Toxoplasma gondii, J. Eukaryot. Microbiol. 44 (6)
(1997) 592–602.
[12] J.P. Dubey, C.A. Speer, S.K. Shen, O.C. Kwok, J.A. Blixt, Oocyst-induced murine
toxoplasmosis: life cycle, pathogenicity, and stage conversion in mice fed
Toxoplasma gondii oocysts, J. Parasitol. 83 (5) (1997) 870–882.
[13] E. Jongert, C.W. Roberts, N. Gargano, E. Förster-Waldl, E. Petersen, Vaccines
against Toxoplasma gondii: challenges and opportunities, Mem. Inst. Oswaldo
Cruz 104 (2) (2009) 252–266.
[14] J.R. Radke, M.J. Gubbels, M.E. Jerome, J.B. Radke, B. Striepen, M.W. White,
Identiﬁcation of a sporozoite-speciﬁc member of the Toxoplasma SAG
superfamily via genetic complementation, Mol. Microbiol. 52 (1) (2004) 93–
105.
[15] S. Gülçe _Iz, M. Döskaya, B. Borrego, F. Rodriguez, Y. Gürüz, I.D. Gürhan, Co-
expression of the Bcl-xL antiapoptotic protein enhances the induction of
Th1-like immune responses in mice immunized with DNA vaccines
encoding FMDV B and T cell epitopes, Vet. Res. Commun. 37 (3) (2013)
187–196.
[16] M. Döskaya, M. Kalantari-Dehaghi, C.M. Walsh, E. Hiszczyn´ska-Sawicka, D.H.
Davies, P.L. Felgner, et al., GRA1 protein vaccine confers better immune
response compared to codon-optimized GRA1 DNA vaccine, Vaccine 25 (10)
(2007) 1824–1837.
[17] T.W. Kim, C.F. Hung, M. Zheng, D.A. Boyd, L. He, S.I. Pai, et al., A DNA vaccine
co-expressing antigen and an anti-apoptotic molecule further enhances the
antigen-speciﬁc CD8+ T-cell immune response, J. Biomed. Sci. 11 (4) (2004)
493–499.
[18] E. Petersen, H.V. Nielsen, L. Christiansen, J. Spenter, Immunization with E. coli
produced recombinant T. gondii SAG1 with alum as adjuvant protect mice
against lethal infection with Toxoplasma gondii, Vaccine 16 (13) (1998) 1283–
1289.
[19] E.A. Mendes, B.C. Caetano, M.L. Penido, O. Bruna-Romero, R.T. Gazzinelli,
MyD88-dependent protective immunity elicited by adenovirus 5 expressing
the surface antigen 1 from Toxoplasma gondii is mediated by CD8(+) T
lymphocytes, Vaccine 29 (27) (2011) 4476–4484.
[20] A.V. Machado, B.C. Caetano, R.P. Barbosa, A.P. Salgado, R.H. Rabelo, C.C. Garcia,
et al., Prime and boost immunization with inﬂuenza and adenovirus encoding
the Toxoplasma gondii surface antigen 2 (SAG2) induces strong protective
immunity, Vaccine 28 (18) (2010) 3247–3256.
[21] M. Zhang, L. Zhao, J. Song, Y. Li, Q. Zhao, S. He, et al., DNA vaccine encoding the
Toxoplasma gondii bradyzoite-speciﬁc surface antigens SAG2CDX protect
BALB/c mice against type II parasite infection, Vaccine 31 (41) (2013) 4536–
4540.
[22] E.V. Lourenço, E.S. Bernardes, N.M. Silva, J.R. Mineo, A. Panunto-Castelo, M.C.
Roque-Barreira, Immunization with MIC1 and MIC4 induces protective
immunity against Toxoplasma gondii, Microbes Infect. 8 (5) (2006) 1244–1251.
[23] G. Dautu, B. Munyaka, G. Carmen, G. Zhang, Y. Omata, X. Xuenan, et al.,
Toxoplasma gondii: DNA vaccination with genes encoding antigens MIC2,
M2AP, AMA1 and BAG1 and evaluation of their immunogenic potential, Exp.
Parasitol. 116 (3) (2007) 273–282.
[24] A.B. Ismael, D. Sekkai, C. Collin, D. Bout, M.N. Mévélec, The MIC3 gene of
Toxoplasma gondii is a novel potent vaccine candidate against toxoplasmosis,
Infect. Immun. 71 (11) (2003) 6222–6228.
[25] G.H. Peng, Z.G. Yuan, D.H. Zhou, X.H. He, M.M. Liu, C. Yan, et al., Toxoplasma
gondii microneme protein 6 (MIC6) is a potential vaccine candidate against
toxoplasmosis in mice, Vaccine 27 (47) (2009) 6570–6574.
[26] M.M. Liu, Z.G. Yuan, G.H. Peng, D.H. Zhou, X.H. He, C. Yan, et al., Toxoplasma
gondii microneme protein 8 (MIC8) is a potential vaccine candidate against
toxoplasmosis, Parasitol. Res. 106 (5) (2010) 1079–1084.
[27] Q. Tao, R. Fang, W. Zhang, Y. Wang, J. Cheng, Y. Li, et al., Protective immunity
induced by a DNA vaccine-encoding Toxoplasma gondii microneme protein 11
against acute toxoplasmosis in BALB/c mice, Parasitol. Res. 112 (8) (2013)
2871–2877.
[28] Z.G. Yuan, D. Ren, D.H. Zhou, X.X. Zhang, E. Petersen, X.Z. Li, et al., Evaluation of
protective effect of pVAX-TgMIC13 plasmid against acute and chronic
Toxoplasma gondii infection in a murine model, Vaccine 31 (31) (2013)
3135–3139.
[29] M. Golkar, M.A. Shokrgozar, S. Rafati, K. Musset, M. Assmar, R. Sadaie, et al.,
Evaluation of protective effect of recombinant dense granule antigens GRA2
and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against
Toxoplasma chronic infection in mice, Vaccine 25 (21) (2007) 4301–4311.
[30] V. Martin, A. Supanitsky, P.C. Echeverria, S. Litwin, T. Tanos, A.R. De Roodt,
et al., Recombinant GRA4 or ROP2 protein combined with alum or the gra4
gene provides partial protection in chronic murine models of toxoplasmosis,
Clin. Diagn. Lab. Immunol. 11 (4) (2004) 704–710.
[31] V. Feliu, V. Vasseur, H.S. Grover, H.H. Chu, M.J. Brown, J. Wang, et al., Location
of the CD8 T cell epitope within the antigenic precursor determines
immunogenicity and protection against the Toxoplasma gondii parasite, PLoS
Pathog. 9 (6) (2013) e1003449.
[32] M. Vercammen, T. Scorza, K. Huygen, J. De Braekeleer, R. Diet, D. Jacobs, et al.,
DNA vaccination with genes encoding Toxoplasma gondii antigens GRA1, GRA7,
and ROP2 induces partially protective immunity against lethal challenge in
mice, Infect. Immun. 68 (1) (2000) 38–45.[33] J.H. Quan, J.Q. Chu, H.A. Ismail, W. Zhou, E.K. Jo, G.H. Cha, et al., Induction of
protective immune responses by a multiantigenic DNA vaccine encoding
GRA7 and ROP1 of Toxoplasma gondii, Clin. Vaccine Immunol. 19 (5) (2012)
666–674.
[34] R. Leyva, P. Hérion, R. Saavedra, Genetic immunization with plasmid DNA
coding for the ROP2 protein of Toxoplasma gondii, Parasitol. Res. 87 (1) (2001)
70–79.
[35] B. Dziadek, J. Gatkowska, M. Grzybowski, J. Dziadek, K. Dzitko, H. Dlugonska,
Toxoplasma gondii: the vaccine potential of three trivalent antigen-cocktails
composed of recombinant ROP2, ROP4, GRA4 and SAG1 proteins against
chronic toxoplasmosis in BALB/c mice, Exp. Parasitol. 131 (1) (2012) 133–
138.
[36] B. Zheng, S. Lu, Q. Tong, Q. Kong, D. Lou, The virulence-related rhoptry protein
5 (ROP5) of Toxoplasma gondii is a novel vaccine candidate against
toxoplasmosis in mice, Vaccine 31 (41) (2013) 4578–4584.
[37] S. Parthasarathy, M.Y. Fong, K. Ramaswamy, Y.L. Lau, Protective immune
response in BALB/c mice induced by DNA vaccine of the ROP8 gene of
Toxoplasma gondii, Am. J. Trop. Med. Hyg. 88 (5) (2013) 883–887.
[38] Q. Liu, F. Wang, G. Wang, Q. Zhao, J. Min, S. Wang, et al., Toxoplasma gondii:
immune response and protective efﬁcacy induced by ROP16/GRA7
multicomponent DNA vaccine with a genetic adjuvant B7–2, Hum. Vaccin.
Immunother. 10 (1) (2013).
[39] D. Qu, J. Han, A. Du, Enhancement of protective immune response to
recombinant Toxoplasma gondii ROP18 antigen by ginsenoside Re, Exp.
Parasitol. 135 (2) (2013) 234–239.
[40] I. Rashid, D. Hedhli, N. Moiré, J. Pierre, F. Debierre-Grockiego, I. Dimier-Poisson,
et al., Immunological responses induced by a DNA vaccine expressing RON4
and by immunogenic recombinant protein RON4 failed to protect mice against
chronic toxoplasmosis, Vaccine 29 (48) (2011) 8838–8846.
[41] A.F. Cuppari, V. Sanchez, B. Ledesma, F.M. Frank, A. Goldman, S.O. Angel, et al.,
Toxoplasma gondii protease inhibitor-1 (TgPI-1) is a novel vaccine candidate
against toxoplasmosis, Vaccine 26 (39) (2008) 5040–5045.
[42] X. Cui, T. Lei, D. Yang, P. Hao, B. Li, Q. Liu, Toxoplasma gondii immune mapped
protein-1 (TgIMP1) is a novel vaccine candidate against toxoplasmosis,
Vaccine 30 (13) (2012) 2282–2287.
[43] R.M. Mohamed, F. Aosai, M. Chen, H.S. Mun, K. Norose, U.S. Belal, et al.,
Induction of protective immunity by DNA vaccination with Toxoplasma gondii
HSP70, HSP30 and SAG1 genes, Vaccine 21 (21–22) (2003) 2852–2861.
[44] H.V. Nielsen, M. Di Cristina, E. Beghetto, A. Spadoni, E. Petersen, N. Gargano,
Toxoplasma gondii: DNA vaccination with bradyzoite antigens induces
protective immunity in mice against oral infection with parasite cysts, Exp.
Parasitol. 112 (4) (2006) 274–279.
[45] J. Chen, S.Y. Huang, D.H. Zhou, Z.Y. Li, E. Petersen, H.Q. Song, et al., DNA
immunization with eukaryotic initiation factor-2a of Toxoplasma gondii
induces protective immunity against acute and chronic toxoplasmosis in
mice, Vaccine (2013). pii: S0264-410X(13)01410-2.
[46] J. Chen, S.Y. Huang, Z.Y. Li, Z.G. Yuan, D.H. Zhou, E. Petersen, et al., Protective
immunity induced by a DNA vaccine expressing eIF4A of Toxoplasma gondii
against acute toxoplasmosis in mice, Vaccine 31 (13) (2013) 1734–1739.
[47] Q. Yu, X. Huang, P. Gong, Q. Zhang, J. Li, G. Zhang, et al., Protective immunity
induced by a recombinant BCG vaccine encoding the cyclophilin gene of
Toxoplasma gondii, Vaccine (2013). pii: S0264-410X(13)01379-0.
[48] N.Z. Zhang, S.Y. Huang, D.H. Zhou, J. Chen, Y. Xu, W.P. Tian, et al., Protective
immunity against Toxoplasma gondii induced by DNA immunization with the
gene encoding a novel vaccine candidate: calcium-dependent protein kinase 3,
BMC Infect. Dis. 13 (1) (2013) 512.
[49] H.L. Wang, Y.Q. Li, L.T. Yin, X.L. Meng, M. Guo, J.H. Zhang, et al., Toxoplasma
gondii protein disulﬁde isomerase (TgPDI) is a novel vaccine candidate against
toxoplasmosis, PLoS One 8 (8) (2013) e70884.
[50] G. Zhao, A. Zhou, G. Lu, M. Meng, M. Sun, Y. Bai, et al., Identiﬁcation and
characterization of Toxoplasma gondii aspartic protease 1 as a novel vaccine
candidate against toxoplasmosis, Parasit. Vectors 6 (2013) 175.
[51] G. Zhao, A. Zhou, G. Lv, M. Meng, M. Sun, Y. Bai, et al., Toxoplasma gondii
cathepsin proteases are undeveloped prominent vaccine antigens against
toxoplasmosis, BMC Infect. Dis. 13 (2013) 207.
[52] H.K. Yan, Z.G. Yuan, H.Q. Song, E. Petersen, Y. Zhou, D. Ren, et al., Vaccination
with a DNA vaccine coding for perforin-like protein 1 and MIC6 induces
signiﬁcant protective immunity against Toxoplasma gondii, Clin. Vaccine
Immunol. 19 (5) (2012) 684–689.
[53] J. Li, Q. Han, P. Gong, T. Yang, B. Ren, S. Li, et al., Toxoplasma gondii rhomboid
protein 1 (TgROM1) is a potential vaccine candidate against toxoplasmosis,
Vet. Parasitol. 184 (2–4) (2012) 154–160.
[54] W.J. Snelling, Q. Lin, J.E. Moore, B.C. Millar, F. Tosini, E. Pozio, et al., Proteomics
analysis and protein expression during sporozoite excystation of
Cryptosporidium parvum (Coccidia, Apicomplexa), Mol. Cell. Proteomics 6 (2)
(2007) 346–355.
[55] H.M. Fritz, K.R. Buchholz, X. Chen, B. Durbin-Johnson, D.M. Rocke, P.A. Conrad,
et al., Transcriptomic analysis of toxoplasma development reveals many novel
functions and structures speciﬁc to sporozoites and oocysts, PLoS One 7 (2)
(2012) e29998.
[56] H.M. Fritz, P.W. Bowyer, M. Bogyo, P.A. Conrad, J.C. Boothroyd, Proteomic
analysis of fractionated Toxoplasma oocysts reveals clues to their
environmental resistance, PLoS One 7 (1) (2012) e29955.
[57] A. Possenti, F. Fratini, L. Fantozzi, E. Pozio, J.P. Dubey, M. Ponzi, et al., Global
proteomic analysis of the oocyst/sporozoite of Toxoplasma gondii reveals
commitment to a host-independent lifestyle, BMC Genomics 14 (2013) 183.
88 S. Gülçe _Iz et al. / Trials in Vaccinology 3 (2014) 81–88[58] M.A. Kutzler, D.B. Weiner, DNA vaccines: ready for prime time?, Nat Rev.
Genet. 9 (10) (2008) 776–788.
[59] Y.B. Chen, M.A. Aon, Y.T. Hsu, L. Soane, X. Teng, J.M. McCaffery, W.C. Cheng, B.
Qi, H. Li, K.N. Alavian, M. Dayhoff-Brannigan, S. Zou, F.J. Pineda, B. O’Rourke,
Y.H. Ko, P.L. Pedersen, L.K. Kaczmarek, E.A. Jonas, J.M. Hardwick, Bcl-xL
regulates mitochondrial energetics by stabilizing the inner membrane
potential, J. Cell Biol. 195 (2) (2011) 263–276.[60] L.P. Billen, C.L. Kokoski, J.F. Lovell, B. Leber, D.W. Andrews, Bcl-XL inhibits
membrane permeabilization by competing with Bax, PLoS Biol. 6 (6) (2008)
e147.
[61] B. Huang, C.P. Mao, S. Peng, L. He, C.F. Hung, T.C. Wu, Intradermal
administration of DNA vaccines combining a strategy to bypass antigen
processing with a strategy to prolong dendritic cell survival enhances DNA
vaccine potency, Vaccine 25 (45) (2007) 7824–7831.
